Cargando…

Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion

BACKGROUND: The trigeminal ganglion (TG) plays a central role in cranial pain. Administration of complete Freund’s adjuvant (CFA) into the temporomandibular joint (TMJ) elicits activation of TG. Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Csáti, A., Edvinsson, L., Vécsei, L., Toldi, J., Fülöp, F., Tajti, J., Warfvinge, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666855/
https://www.ncbi.nlm.nih.gov/pubmed/26627709
http://dx.doi.org/10.1186/s10194-015-0581-x
_version_ 1782403748048404480
author Csáti, A.
Edvinsson, L.
Vécsei, L.
Toldi, J.
Fülöp, F.
Tajti, J.
Warfvinge, K.
author_facet Csáti, A.
Edvinsson, L.
Vécsei, L.
Toldi, J.
Fülöp, F.
Tajti, J.
Warfvinge, K.
author_sort Csáti, A.
collection PubMed
description BACKGROUND: The trigeminal ganglion (TG) plays a central role in cranial pain. Administration of complete Freund’s adjuvant (CFA) into the temporomandibular joint (TMJ) elicits activation of TG. Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect. We hypothesize that KYNA may reduce CFA-induced activation within the TG. METHODS: A local inflammation was induced by administration of CFA into the TMJ in rats. KYNA and kynurenic acid amide 2 (KYNAA2) were intraperitoneally administered. We investigated changes of mitogen-activated protein kinases (MAPKs as ERK1/2, p38 and SAPK/JNK), NF-κB, CaMKII and DREAM, in addition to calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in the TG, with immunohistochemistry and Western blot at 2 and 10 days post-CFA injection. RESULTS: We showed CFA-induces increases in pERK1/2, pp38, CaMKII, NF-κB and DREAM immunohistochemistry after 2 and 10 days. KYNAA2 displayed stronger effects on MAPKs than KYNA. Increased expression of CaMKII, NF-κB and DREAM were found in the neurons. Western blot showed significantly increase in pERK expression at 10 days post-CFA, which decreased after 10 days of KYNA treatment. Two days post-CFA, a significantly increase in pp38 expression was found, which decreased after 2 days of KYNA and KYNAA2 treatment. CONCLUSIONS: The CFA-induced inflammatory model for the TG activation provided a time-related expression of MAPK (pERK1/2, pp38) and NF-κB. It involves both the neuronal and glial activation, which points to possible neuron-glia interactions during this process. The administration of the endogenous NMDA-receptor antagonists, KYNA and its derivative KYNAA2, resulted in the inhibition of the induced signaling system of the TG, which further points the importance of the glutamate receptors in this mechanism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s10194-015-0581-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4666855
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-46668552015-12-11 Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion Csáti, A. Edvinsson, L. Vécsei, L. Toldi, J. Fülöp, F. Tajti, J. Warfvinge, K. J Headache Pain Research Article BACKGROUND: The trigeminal ganglion (TG) plays a central role in cranial pain. Administration of complete Freund’s adjuvant (CFA) into the temporomandibular joint (TMJ) elicits activation of TG. Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect. We hypothesize that KYNA may reduce CFA-induced activation within the TG. METHODS: A local inflammation was induced by administration of CFA into the TMJ in rats. KYNA and kynurenic acid amide 2 (KYNAA2) were intraperitoneally administered. We investigated changes of mitogen-activated protein kinases (MAPKs as ERK1/2, p38 and SAPK/JNK), NF-κB, CaMKII and DREAM, in addition to calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in the TG, with immunohistochemistry and Western blot at 2 and 10 days post-CFA injection. RESULTS: We showed CFA-induces increases in pERK1/2, pp38, CaMKII, NF-κB and DREAM immunohistochemistry after 2 and 10 days. KYNAA2 displayed stronger effects on MAPKs than KYNA. Increased expression of CaMKII, NF-κB and DREAM were found in the neurons. Western blot showed significantly increase in pERK expression at 10 days post-CFA, which decreased after 10 days of KYNA treatment. Two days post-CFA, a significantly increase in pp38 expression was found, which decreased after 2 days of KYNA and KYNAA2 treatment. CONCLUSIONS: The CFA-induced inflammatory model for the TG activation provided a time-related expression of MAPK (pERK1/2, pp38) and NF-κB. It involves both the neuronal and glial activation, which points to possible neuron-glia interactions during this process. The administration of the endogenous NMDA-receptor antagonists, KYNA and its derivative KYNAA2, resulted in the inhibition of the induced signaling system of the TG, which further points the importance of the glutamate receptors in this mechanism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s10194-015-0581-x) contains supplementary material, which is available to authorized users. Springer Milan 2015-12-01 /pmc/articles/PMC4666855/ /pubmed/26627709 http://dx.doi.org/10.1186/s10194-015-0581-x Text en © Csáti et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Csáti, A.
Edvinsson, L.
Vécsei, L.
Toldi, J.
Fülöp, F.
Tajti, J.
Warfvinge, K.
Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title_full Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title_fullStr Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title_full_unstemmed Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title_short Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
title_sort kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666855/
https://www.ncbi.nlm.nih.gov/pubmed/26627709
http://dx.doi.org/10.1186/s10194-015-0581-x
work_keys_str_mv AT csatia kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT edvinssonl kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT vecseil kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT toldij kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT fulopf kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT tajtij kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion
AT warfvingek kynurenicacidmodulatesexperimentallyinducedinflammationinthetrigeminalganglion